Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2) Positive Australian Patient
Not Applicable
Recruiting
- Conditions
- HER2 positive metastatic breast cancerCancer - Breast
- Registration Number
- ACTRN12615000232538
- Lead Sponsor
- BioGrid Australia Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Patients of any age and any level of fitness with HER2+ metastatic breast cancer, of any hormone receptor status, either recurrent or de novo metastatic disease, who have either been diagnosed with metastatic disease within the last 3-6 months or who have progressed on 1st line therapy in the last 3-6 months
Exclusion Criteria
- Patients with HER2+ metastatic breast cancer who have received more than two lines of therapy already
- Patients who are not Australian citizens or are otherwise ineligible for systemic treatment subsidised by the Pharmaceutical Benefit Scheme
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method